media – Page 598 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Naidex 2018 Press Release| Drugdu.com

Naidex is Europe's most exciting event dedicated to the disability, independent living and healthcare professional sectors. In the wake of the huge success of the most recent instalment of this esteemed and long-established event, Naidex will return for its 44th year to the Birmingham NEC on the 25th & 26th April 2018.
- Source: Naidex
- 820
- January 11, 2018
Exhibitions & Activities Naidex
Introduction about Vietnam Medi-Pharm Expo

We would like to invite your participation in the below largest and most prestigous MEDICAL & PHARMACEUTICAL exhibitions in Ho Chi Minh City and Hanoi City (Vietnam):
- Source: Ddu
- 1,223
- January 11, 2018
Exhibitions & Activities Medi-Pharm Expo pharmaceutical Vietnam
2018 MEDICARE TAIWAN & SenCARE Call for Application

The 2018 MEDICARE TAIWAN (Taiwan International Medical & Healthcare Exhibition) and SenCARE (Taiwan International Senior Lifestyle and Health Care Show), the biggest medical and healthcare show in Taiwan, will be held from June 21 – 24, 2018, at Taipei World Trade Center Exhibition Hall 1(TWTC).
- Source: Ddu
- 723
- January 11, 2018
Exhibitions & Activities Medicare SenCARE
Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**

Novartis announced the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS). SURPASS is the first head-to-head clinical trial in AS investigating superiority of Cosentyx in slowing spinal bone damage versus proposed biosimilar adalimumab**. SURPASS is currently recruiting patients, with the 'first patient first visit' already achieved in November 2017.
- Source: drugdu
- 736
- January 11, 2018
adalimumab** Company Insight Cosentyx® Novartis Researches
Women who work nights face higher cancer risk

Women who regularly work the night shift in Europe and North America may face a 19 percent higher risk of cancer than those who work during the day, said a study Monday.
- Source: msn
- 593
- January 11, 2018
breast cancer cancer Researches
Fitbit has invested $6 million in glucose-monitoring startup Sano

Fitbit has invested $6 million in a glucose-monitoring startup called Sano, in what appears to be part of Fitbit’s larger plans to make its fitness devices more valuable for overall health.
- Source: The Verge
- 410
- January 11, 2018
Company Insight Glucose Monitoring System wearables
Microsoft Wants to Use Artificial Intelligence to Make CRISPR More Accurate

he gene-editing technology CRISPR could very well one day rid the world of its most devastating diseases, allowing us to simply edit away the genetic code responsible for an illness. One of the things standing in the way of turning that fantasy into reality, though, is the problem of off-target effects. Now Microsoft is hoping to use artificial intelligence to fix this problem.
- Source: GIZMODO
- 427
- January 11, 2018
AI CRISPR Microsoft Researches
Is the $850,000 price tag for a blindness-curing gene therapy a sign of future medical costs?

Gene therapies are an undeniably exciting new frontier for medicine. From Kymriah's genetically modified, cancer-hunting immune cells, to Luxturna's vision-restoring healthy gene replacement, these therapies are fundamentally unlike 20th-century medicines which generally require ongoing drug treatment. Gene therapies can be one-off doses that in effect, cure a specific disease.
- Source: New Atlas
- 455
- January 11, 2018
FDA Gene therapy Market Views
Two Former Receptos Execs Launch New San Diego Biotech Startup With $100M

Gossamer Bio is launching with $100 million in seed financing and two biotech heavy hitters as leadership.
- Source: drugdu
- 495
- January 10, 2018
Crohn’s disease Market Views multiple sclerosis Series ulcerative colitis
Ionis’ Inotersen NDA Accepted for Priority Review by the FDA

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced that its New Drug Application (NDA) for inotersen has been accepted for Priority Review by the U.S. Food and Drug Administration (FDA). Inotersen is an investigational drug for the treatment of patients with hereditary TTR amyloidosis (hATTR). Priority Review is granted by the FDA to drugs with the potential to address a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of July 6, 2018. “TTR amyloidosis is a progressive, fatal disease with very limited treatment options. Receiving Priority Review in the U.S. and Accelerated Assessment in the EU for inotersen shows that the regulatory agencies recognize the high unmet need and the urgency to identify effective therapies to treat patients with this devastating disease,” said Sarah ...
- Source: Prnewswire;
- 484
- January 10, 2018
FDA hATTR New Approvals TTR amyloidosis

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.